With the FDA approval of Gilead's seladelpar, there have now been two in a matter of weeks. The US agency has cleared seladelpar under the Livdelzi brand name as a second-line therapy for PBC in ...

Competition in the PBC category could come later this year from Gilead Sciences’ PPAR delta agonist seladelpar, which is set for an FDA decision by 14th August as a second-line PBC treatment.

The most recent trading session ended with Gilead Sciences (GILD) standing at $91.41, reflecting a -0.51% shift from the previouse trading day's closing. The stock's performance was behind the S&P ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The FDA’s Center for Drug Evaluation and Research (CDER) approved 50 new small molecules, biologics and oligonucleotide therapeutics last year. The class of 2024 was a little smaller than that ...

After hours: January 3 at 6:54:26 PM EST Loading Chart for GILD ...

The division, which will expand on the already-existing Released Soldiers’ Division and Fund, will include a dedicated branch for reservists’ welfare and be led by Col. (res.) Eyal Hans ...

After hours: January 3 at 6:54:26 p.m. EST ...